Plain-English translation of NCT07320625 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether a medication called can help reduce damage to your heart after you've had a heart attack and received emergency treatment to restore blood flow. Researchers believe this medication may protect your heart tissue from additional injury that can happen during the recovery process. The goal is to see if this treatment can improve your heart function and long-term health.
Even with the best emergency treatments available, many heart attack patients experience ongoing heart damage and a significant number go on to develop heart failure. This medication targets a biological pathway that researchers believe contributes to this additional injury, so this trial is testing whether blocking that pathway could improve outcomes and reduce complications.
You likely qualify if…
You likely don't qualify if…
After your emergency heart treatment, you will be randomly assigned to receive either or a placebo (inactive pill) and will take it daily. You will have follow-up visits where doctors will monitor your heart function, perform imaging tests, and check your blood work to see how well your heart is recovering. The study will track your health outcomes over time to see if the medication provides benefits compared to placebo.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
China
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.